{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:23:55Z","timestamp":1777289035805,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T00:00:00Z","timestamp":1362528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Transrectal ultrasound guided prostate biopsies (TRUSBx) are associated with a spectrum of complications, including most significantly infection, which affects up to 5% of patients. In the most severe cases, infection leads to sepsis, a life\u2010threatening complication. Escherichia coli is the primary responsible pathogen. Although antibiotic prophylaxis with fluoroquinolones is routinely used, there is evidence that the infection rate after TRUSBx is increasing, and this appears to be due to an increasing prevalence of ciprofloxacin\u2010resistant rectal flora.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This is the largest prospective clinical trial to date analysing the rectal flora of men undergoing prostate biopsies. We determined the microbial and antibiotic sensitivity profiles from 849 patients. Ciprofloxacin\u2010resistant Gram\u2010negative organisms were identified in the rectal flora of 19.0% of men. Furthermore, fluoroquinolone use within 6 months preceding a TRUSBx and the presence of a prosthetic heart valve were significant predictors of ciprofloxacin resistance on rectal swab. Determining the prevalence of rectal fluoroquinolone resistance has important implications in evaluation of the suitability of prophylactic regimens. Antimicrobial profiles derived from rectal swabs pre\u2010biopsy may prove useful in guiding targeted antibiotic prophylaxis.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To establish the prevalence of ciprofloxacin\u2010resistant bacteria in patients undergoing transrectal ultrasound guided prostate biopsies (\n                            <jats:styled-content style=\"fixed-case\">TRUSBx<\/jats:styled-content>\n                            ) and to determine whether this predicts subsequent infectious complications.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>To identify risk factors for harbouring ciprofloxacin\u2010resistant flora.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Any patient undergoing a\n                            <jats:styled-content style=\"fixed-case\">TRUSBx<\/jats:styled-content>\n                            from 2009 to 2011 was eligible for enrolment in this prospective study.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Pre\u2010biopsy rectal and urine cultures and post\u2010biopsy urine cultures were obtained and antimicrobial susceptibility was determined.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Univariate and multivariate analyses were performed to identify independent patient risk factors associated with ciprofloxacin\u2010resistant rectal flora.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            A total of 865 patients underwent\n                            <jats:styled-content style=\"fixed-case\">TRUSBx<\/jats:styled-content>\n                            , of whom 19.0% were found to have ciprofloxacin\u2010resistant\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            ram\u2010negative coliforms.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>\n                              <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>\n                              scherichia coli\n                            <\/jats:italic>\n                            was the most prevalent\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            ram\u2010negative rectal isolate (80.9%) and accounted for 90.6% of ciprofloxacin resistance.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Patient characteristics that conferred an increased risk of harbouring ciprofloxacin\u2010resistant organisms included a history of a heart valve replacement (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.05) and ciprofloxacin use in the past 3 months (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.05).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Infectious complications were observed in 3.6% (\n                            <jats:italic>n<\/jats:italic>\n                            = 31) of the patient population and 48% of these patients grew ciprofloxacin\u2010resistant organisms on the pre\u2010biopsy rectal swab (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Antimicrobial resistance to ciprofloxacin in the rectal flora was common, particularly in patients with recent ciprofloxacin use and a heart valve replacement.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Despite a significant correlation between those patients who developed infections and the detection of ciprofloxacin\u2010resistant organisms, only 9.0% (\n                            <jats:italic>n<\/jats:italic>\n                            = 15) of the total group with ciprofloxacin resistance developed an infectious complication.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Future studies will need to evaluate the cost effectiveness and clinical utility of a pre\u2010biopsy rectal culture in targeting antibiotic prophylaxis.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11637.x","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T13:57:28Z","timestamp":1362578248000},"page":"946-953","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy"],"prefix":"10.1111","volume":"111","author":[{"given":"Stephen","family":"Taylor","sequence":"first","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Margolick","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeid","family":"Abughosh","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Larry","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Bowie","sequence":"additional","affiliation":[{"name":"Department of Medicine University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Roscoe","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Machan","sequence":"additional","affiliation":[{"name":"Department of Radiology University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Urologic Sciences University of British Columbia  Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09294.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.078"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.058"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.11.088"},{"key":"e_1_2_8_6_1","unstructured":"American Urological Associated.Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis 2007. Available at:http:\/\/www.auanet.org\/content\/media\/antimicroprop08.pdf"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.01.068"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.11.043"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000061280.23447.29"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02089.x"},{"key":"e_1_2_8_11_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty\u2010First Informational Supplement","author":"CLSI","year":"2011"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199206000-00025"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03638.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.11.115"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.04.044"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.10.071"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0862-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01228-08"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.02.065"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.04.064"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09715.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11637.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:37:29Z","timestamp":1761748649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11637.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11637.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11637.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,6]]},"assertion":[{"value":"2013-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}